PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression.
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 493 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Myelodysplastic syndromesThis series is part of our curated briefing on it.
- Samples
- 493 samples: 6 conditions, mostly with about 42 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- PU.1-activated genomic regions define low-risk MDS subsets characterized by immune dysregulation and disease progressionBlood · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE298020_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1267114 and SRA study SRP604274. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 400 samples.
How we read this: 6 replicated groups read from the first 400 of 493 sample titles; they account for 400 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9001853 H3K27Ac_LR_patient_sample_214 H3K27Ac_LR_patient_samp…
- GSM9001854 H3K27Ac_HR_patient_sample_218 H3K27Ac_HR_patient_samp…
- GSM9001855 H3K27Ac_LR_patient_sample_3 H3K27Ac_LR_patient_samp…
- GSM9001856 H3K27Ac_LR_patient_sample_4 H3K27Ac_LR_patient_samp…
- GSM9001857 H3K27Ac_LR_patient_sample_5 H3K27Ac_LR_patient_samp…
- GSM9001858 H3K27Ac_AML_patient_sample_6 H3K27Ac_AML_patient_sam…
- GSM9001859 H3K27Ac_AML_patient_sample_7 H3K27Ac_AML_patient_sam…
- GSM9001860 H3K27Ac_HR_patient_sample_8 H3K27Ac_HR_patient_samp…
- GSM9001861 H3K27Ac_LR_patient_sample_9 H3K27Ac_LR_patient_samp…
- GSM9001862 H3K27Ac_LR_patient_sample_10 H3K27Ac_LR_patient_samp…
- GSM9001863 H3K27Ac_HR_patient_sample_11 H3K27Ac_HR_patient_samp…
- GSM9001864 H3K27Ac_LR_patient_sample_12 H3K27Ac_LR_patient_samp…
- GSM9001865 H3K27Ac_LR_patient_sample_13 H3K27Ac_LR_patient_samp…
- GSM9001866 H3K27Ac_LR_patient_sample_14 H3K27Ac_LR_patient_samp…
- GSM9001867 H3K27Ac_LR_patient_sample_15 H3K27Ac_LR_patient_samp…
- GSM9001868 H3K27Ac_AML_patient_sample_16 H3K27Ac_AML_patient_sam…
- GSM9001869 H3K27Ac_LR_patient_sample_17 H3K27Ac_LR_patient_samp…
- GSM9001870 H3K27Ac_LR_patient_sample_18 H3K27Ac_LR_patient_samp…
- GSM9001871 H3K27Ac_HR_patient_sample_19 H3K27Ac_HR_patient_samp…
- GSM9001872 H3K27Ac_AML_patient_sample_20 H3K27Ac_AML_patient_sam…
- GSM9001873 H3K27Ac_LR_patient_sample_197 H3K27Ac_LR_patient_samp…
- GSM9001874 H3K27Ac_LR_patient_sample_22 H3K27Ac_LR_patient_samp…
- GSM9001875 H3K27Ac_LR_patient_sample_23 H3K27Ac_LR_patient_samp…
- GSM9001876 H3K27Ac_LR_patient_sample_24 H3K27Ac_LR_patient_samp…
- GSM9001877 H3K27Ac_LR_patient_sample_25 H3K27Ac_LR_patient_samp…
- GSM9001878 H3K27Ac_LR_patient_sample_26 H3K27Ac_LR_patient_samp…
- GSM9001879 H3K27Ac_AML_patient_sample_27 H3K27Ac_AML_patient_sam…
- GSM9001880 H3K27Ac_AML_patient_sample_28 H3K27Ac_AML_patient_sam…
- GSM9001881 H3K27Ac_HR_patient_sample_29 H3K27Ac_HR_patient_samp…
- GSM9001882 H3K27Ac_LR_patient_sample_30 H3K27Ac_LR_patient_samp…
- GSM9001883 H3K27Ac_LR_patient_sample_31 H3K27Ac_LR_patient_samp…
- GSM9001884 H3K27Ac_LR_patient_sample_32 H3K27Ac_LR_patient_samp…
- GSM9001885 H3K27Ac_AML_patient_sample_33 H3K27Ac_AML_patient_sam…
- GSM9001886 H3K27Ac_AML_patient_sample_34 H3K27Ac_AML_patient_sam…
- GSM9001887 H3K27Ac_AML_patient_sample_35 H3K27Ac_AML_patient_sam…
- GSM9001888 H3K27Ac_AML_patient_sample_36 H3K27Ac_AML_patient_sam…
- GSM9001889 H3K27Ac_AML_patient_sample_37 H3K27Ac_AML_patient_sam…
- GSM9001890 H3K27Ac_AML_patient_sample_38 H3K27Ac_AML_patient_sam…
- GSM9001891 H3K27Ac_AML_patient_sample_39 H3K27Ac_AML_patient_sam…
- GSM9001892 H3K27Ac_LR_patient_sample_121 H3K27Ac_LR_patient_samp…
+ 453 more — browse all 493 samples with per-sample file links →
- GSE298729 Chromatin accessibility of hematopoietic stem/progenitor cells (HSPCs) derived from MDS patients before and after disease progression 2 samples same disease briefing · shares mds, progression
- GSE264117 Investigating microenvironment in MDS II 503 samples same disease briefing · shares mds
- GSE275000 Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs 104 samples same disease briefing · shares mds
- GSE281562 Unique epigenomic signatures identify biologically significant subtypes of MDS and predict response to azacytidine [RNA-Seq] 83 samples same disease briefing · shares mds
- GSE31174 Affymetrix SNP array data for myelodysplastic syndromes (MDS) and related neoplasms 58 samples same disease briefing · shares mds
- GSE326589 Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS 58 samples same disease briefing · shares mds
- GSE211032 Expression Analysis (RNA-Seq) of adult Myelodysplastic Syndromes (MDS)/Acute Myeloid Leukemia (AML) with isolated monosomy 7 compared to controls 45 samples same disease briefing · shares mds
- GSE270760 PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7 (CUT&Tag) 24 samples same disease briefing · shares mds
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.